The use of an exogenous pulmonary
surfactant (EPS) to deliver other
relevant drugs to the lungs is a promising strategy for combined therapy.
We evaluated the interaction of polymyxin B (PxB) with a clinically
used EPS, the poractant alfa Curosurf (PSUR). The effect of PxB on
the protein-free model system (MS) composed of four phospholipids
(diC16:0PC/16:0–18:1PC/16:0–18:2PC/16:0–18:1PG)
was examined in parallel to distinguish the specificity of the composition
of PSUR. We used several experimental techniques (differential scanning
calorimetry, small- and wide-angle X-ray scattering, small-angle neutron
scattering, fluorescence spectroscopy, and electrophoretic light scattering)
to characterize the binding of PxB to both EPS. Electrostatic interactions
PxB–EPS are dominant. The results obtained support the concept
of cationic PxB molecules lying on the surface of the PSUR bilayer,
strengthening the multilamellar structure of PSUR as derived from
SAXS and SANS. A protein-free MS mimics a natural EPS well but was
found to be less resistant to penetration of PxB into the lipid bilayer.
PxB does not affect the gel-to-fluid phase transition temperature, T
m, of PSUR, while T
m increased by ∼+ 2 °C in MS. The decrease of the thickness
of the lipid bilayer (d
L) of PSUR upon
PxB binding is negligible. The hydrophobic tail of the PxB molecule
does not penetrate the bilayer as derived from SANS data analysis
and changes in lateral pressure monitored by excimer fluorescence
at two depths of the hydrophobic region of the bilayer. Changes in d
L of protein-free MS show a biphasic dependence
on the adsorbed amount of PxB with a minimum close to the point of
electroneutrality of the mixture. Our results do not discourage the
concept of a combined treatment with PxB-enriched Curosurf. However,
the amount of PxB must be carefully assessed (less than 5 wt % relative
to the mass of the surfactant) to avoid inversion of the surface charge
of the membrane.